Denmark's Voltabak shortage to mid-May 2027 shows how fragile single-source supply is
DKMA's updated notice on Laboratoires Thea's diclofenac eye drops, with the Methergin withdrawal and estradiol patch notices, shows how Denmark manages supply failures.
What the notice says
On 13 November 2026 the Danish Medicines Agency (DKMA) updated its supply notice for Voltabak, Laboratoires Thea's diclofenac eye drops. Quality problems are disrupting supply, and the shortage is now expected to run to mid-May 2027. That is roughly six months from the date of the update. DKMA is allowing foreign packs to be supplied under section 29(2) of the Medicines Act.
The records do not say which quality problem is involved, which strengths or pack sizes are affected, or how many patients rely on the product. They also do not say whether the mid-May date is a firm restock forecast or a planning estimate. Teams should treat it as DKMA's current expectation, which the agency may revise again.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources this analysis is based on
- Denmark updates Voltabak eye drop supply notice, with shortage expected to run to mid-May 2027 DKMA · Fri 13 Nov 2026
- Medicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filing PAVmed Inc. · Fri 13 Nov 2026
- Methergin 0.2 mg/ml injection withdrawn from Danish market, DKMA reports DKMA · Fri 13 Nov 2026
- Denmark updates import window for estradiol 25 microgram patches in supply failure DKMA · Fri 13 Nov 2026
- DKMA updates Vivelle Dot 37.5 supply notice: shortage expected to last until end of December DKMA · Fri 13 Nov 2026
- Intersurgical breathing systems: connectors can detach from Smoothbore tube, IGJ posts safety notice IGJ · Thu 12 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
FTC's bid to block Covetrus-MWI puts veterinary distribution, and PV information flow, in focus
The US suit against a $3.5bn merger of the two largest vet distributors is an antitrust case, but animal-health PV teams should check how safety information moves through the channel.
Vercise DBS instruction recall: why IFU corrections matter to trial teams
Health Canada's Type II recall of Vercise clinician programmer instructions is narrow, but it shows how a labelling correction can ripple into protocols, training and site files.
Illinois Medicaid charges show no pharma link, but the compliance signal is worth reading
Illinois's attorney general has charged three people in two Medicaid fraud cases, with no stated link to medicines. For quality and compliance teams, the context around it matters more than the case.